Population pharmacokinetic modeling of vedolizumab for graft-versus-host disease prophylaxis in adults with allogeneic hematopoietic stem cell transplant.

Autor: Waterhouse T; Metrum Research Group, Tariffville, Connecticut, USA., Baron K; Metrum Research Group, Tariffville, Connecticut, USA., Eure W; Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA., Chen C; Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA., Dirks NL; Metrum Research Group, Tariffville, Connecticut, USA., Jansson J; Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA., Akbari M; Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA., Mehrotra S; Takeda Pharmaceuticals Inc., Cambridge, Massachusetts, USA.

Publikováno v: Pharmacology research & perspectives [Pharmacol Res Perspect] 2024 Oct; Vol. 12 (5), pp. e1257.

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn's disease.

Autor: Okamoto H; Takeda PRA Development Center KK, Osaka, Japan., Dirks NL; Metrum Research Group, Tariffville, CT, USA., Rosario M; Takeda Development Center Americas Inc, Cambridge, MA, USA., Hori T; Takeda Pharmaceutical Company Limited, Osaka, Japan., Hibi T; Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.

Publikováno v: Intestinal research [Intest Res] 2021 Jan; Vol. 19 (1), pp. 95-105. Date of Electronic Publication: 2020 Jul 10.

Corrigendum: Exposure-efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn's Disease.

Autor: Rosario M; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., French JL; Metrum Research Group LLC, Tariffville, CT, USA., Dirks NL; Metrum Research Group LLC, Tariffville, CT, USA., Sankoh S; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Parikh A; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Yang H; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA., Danese S; Inflammatory Bowel Disease Clinical and Research Unit, Istituto Clinico Humanitas, Milan, Italy., Colombel JF; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA., Smyth M; Takeda Development Centre Europe Ltd, London, UK., Sandborn WJ; Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA., Feagan BG; Robarts Research Institute, University of Western Ontario, London, ON, Canada., Reinisch W; Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, and Department of Internal Medicine, McMaster University, Hamilton, ON, Canada., Sands BE; Icahn School of Medicine at Mount Sinai Hospital, New York, NY, USA., Sans M; Digestive Diseases Service, Centro Médico Teknon, Barcelona, Spain., Fox I; Clinical Pharmacology Department, Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Ltd, Cambridge, MA, USA.

Publikováno v: Journal of Crohn's & colitis [J Crohns Colitis] 2018 Mar 28; Vol. 12 (4), pp. 510.

Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma.

Autor: Zhu R; Genentech, Inc., South San Francisco, CA, USA., Zheng Y; Genentech, Inc., South San Francisco, CA, USA., Dirks NL; Metrum Research Group, CT, USA., Vadhavkar S; Genentech, Inc., South San Francisco, CA, USA., Jin JY; Genentech, Inc., South San Francisco, CA, USA., Peng K; Genentech, Inc., South San Francisco, CA, USA., Holweg CTJ; Genentech, Inc., South San Francisco, CA, USA., Olsson J; Genentech, Inc., South San Francisco, CA, USA., Matthews JG; Genentech, Inc., South San Francisco, CA, USA., Putnam WS; Genentech, Inc., South San Francisco, CA, USA. Electronic address: Putnam.Wendy@gene.com.

Publikováno v: Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2017 Oct; Vol. 46, pp. 88-98. Date of Electronic Publication: 2017 Aug 24.

Corrigendum: 2016 ACG Abstracts-Inflammatory Bowel Disease.

Autor: Osterman M, Gastonguay MR, Lasch K, Barocas MA, Rosario M, Wilbur JD, Dirks NL

Publikováno v: The American journal of gastroenterology [Am J Gastroenterol] 2017 Jul; Vol. 112 (7), pp. 1209-1210. Date of Electronic Publication: 2017 Jan 10.